• Results for the Fourth Quarter 2023

    Currency neutral sales of own products was down 17.4 % for the quarter and down 5.1 % for the year. Download the full report and presentation, and watch the video recording from the webinar below.…

    Read more
  • Presentation of Medistim’s Q4 2023 Financial Results

    The financials will be presented via a live webinar on Thursday, February 29 from 09:00-10:00 (CEST). Representatives for the company will be President and CEO Kari Eian Krogstad and CFO Thomas Jakobsen. The recording will…

    Read more
  • Medistim is opening a direct sales office in Sweden

    This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company’s global growth strategy. The company is well positioned to continue its growth by further…

    Read more
  • Results for the Third Quarter 2023

    Currency neutral sales of own products was down 5.6% for the quarter and up 1.2% YTD September. Operating profit (EBIT) for the quarter ended at MNOK 34 giving a 27.0% EBIT margin (MNOK 34, a…

    Read more
  • Presentation of Medistim’s Q3 2023 Financial Results

    The financials will be presented via a live webinar on Friday, October 27 from 08:00-09:00 (CEST). Representatives for the company will be President and CEO Kari Eian Krogstad and CFO Thomas Jakobsen. The recording will be…

    Read more
  • Results for the Second Quarter and First Half 2023

    Currency-neutral sales of own products were up 4.0% for the quarter and 2.5% for the first half. Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin of…

    Read more
  • Presentation of Medistim’s Q2 2023 Financial Results

    The financials will be presented via a live webinar on Thursday, August 31st from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…

    Read more
  • Medistim announces partnership with ROMA-Women Trial

    Medistim is pleased to announce its partnership with ROMA-Women, a groundbreaking cardiac surgery trial that is specifically focused on women. Historically, cardiovascular research and treatment protocols have primarily focused on men, leaving women underrepresented in…

    Read more
  • Results for the First Quarter 2023

    NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…

    Read more
  • Presentation of Medistim’s Q1 2023 Financial Results

    The financials will be presented via a live webinar on Tuesday, April 25th from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…

    Read more